Abstract: Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.

Abstract: A method of treating familial hypercholesterolemia accelerated atherosclerosis in a subject in need thereof, comprising administering an effective amount of a dicarbonyl scavenger.

Abstract: Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.

Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof.

Abstract: Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.

Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof.

Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.

Abstract: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.

Abstract: A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.

Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.

Abstract: Methods are provided for diagnosis, prognosis, and treatment associated with a cardiovascular event in a subject as well as methods of providing anti-platelet therapy. The methods can comprise obtaining a sample from the subject, and determining the presence of at least two single nucleotide polymorphisms (SNP) in the sample selected from Rs7541936 in PTGER3, Rs977214 in PTGER3, and Rs2206343 in PTGER3. The methods can also comprise determining the presence in the sample of Rs4383756 in PTGER4. Some methods comprise administering conventional anti-platelet therapy to the subject if Rs4383756 in PTGER4 is present in the sample. Furthermore, some methods comprise administering an EP3 antagonist and/or conventional anti-platelet therapy to the subject if Rs4383756 in PTGER4 is not present in the sample. The cardiovascular event can involve thrombosis or an embolic event, a myocardial infarction, a stroke, a primary cardiovascular event, or coronary artery disease.

Abstract: A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.

Abstract: Compounds, compositions and methods related to the prevention or treatment of isoprostane-mediated tissue damage in a mammalian subject in need thereof.

Abstract: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.

Abstract: Method of inhibiting formation of levuglandin adducts of histone and DNA in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.

Abstract: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.

Abstract: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.

Abstract: Alzheimer's disease (AD) is characterized by the accumulation of amyloid-? peptide (A?) in the brain. A? is derived from amyloid precursor protein (APP) by ?- and ?-secretases, with the ? form (sAPP?) being associated with the disease state, and the ? form (sAPP?) being associated with the non-disease state. The present inventor proposes that defined the ratio of sAPP? to sAPP? or the ratio of CTF? to CTF? provide and accurate diagnosis of the disease, as well as a predictor for asymptomatic patients at risk of developing AD. In addition, drug screening and monitoring of treatment effectiveness can exploit this same sAPP?/sAPP? or CTF?/CTF? ratio.

Abstract: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.